Hemostemix (TSE:HEM) has released an update.
Hemostemix Inc., a pioneering autologous stem cell therapy company, has announced a private placement aiming to raise up to $4,000,000 through the sale of Common Shares and Warrants. This strategic financing move is expected to fuel the company’s growth and advance the development and commercialization of its innovative blood-based stem cell therapeutic platform and lead product, ACP-01.
For further insights into TSE:HEM stock, check out TipRanks’ Stock Analysis page.
